Navigation Links
Endo Pharmaceuticals Completes Next Step in Regulatory Process for FORTESTA™ for Men With Low Testosterone
Date:7/1/2010

has provided information in the Complete Response about its plans for a post-approval "hand-wash" study.

LOW T

Low T, also known as hypogonadism, is a condition in men characterized by the body's failure to produce normal amounts of the hormone testosterone.  It is associated with symptoms including decreased energy and mood, fatigue, loss of muscle mass, decreased libido and erectile dysfunction.  Because the symptoms of Low T are often similar to those caused by other medical conditions, more than 91 percent of men with the condition go undiagnosed.  

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, prostate cancer, bladder cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM®, a topical patch to relieve the pain of postherpetic neuralgia; Percocet® and Percodan® tablets for the relief of moderate-to-moderately severe pain; FROVA® tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA® tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA® ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; Voltaren® Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; VANTAS® for the palliative treatment of advanced prostate cancer; SUPPRELIN® LA for the treatment of early onset puberty in children; and VA
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Silicon Valley Bank, the bank ... today that examines the merger, acquisition and IPO ... According to the annual report based on 2013 data, ... since SVB started tracking the data in 2005. ... on solid healthcare M&A activity over the last few ...
(Date:7/30/2014)... and SAN DIEGO , July 30, ... ARNA ) announced today that an article based on ... lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, and ... recently published in the online issue of Obesity , ... objective of these analyses was to identify whether there is ...
(Date:7/30/2014)... NEW YORK , July 30, 2014 ... of new products for oncology supportive care, announced that ... has been featured in an article on OncLive.com titled, ... Head and Neck Cancers."  Dr. Steve Sonis , ... the growing demand seen in the oncology community for ...
Breaking Medicine Technology:Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3
... 2012  A new nationwide survey finds that on ... questions from customers about vitamins and supplements as ... prescription medications.  The study also reveals pharmacists, top ... topics customers do ask about. (Photo: ...
... 2012 Marking a major milestone for the ... developer of oral drug delivery systems, announced today that it ... Patent Office. The patent covers an important part of the ... peptides. Oramed,s portfolio now consists of one issued patent and ...
Cached Medicine Technology:Top OTC Secrets From Your Pharmacist 2Top OTC Secrets From Your Pharmacist 3Top OTC Secrets From Your Pharmacist 4Oramed Pharmaceuticals Granted Australian Patent for Important Part of the Company's Core Technology in Oral Delivery of Proteins 2
(Date:7/30/2014)... Pawtucket, Rhode Island (PRWEB) July 30, 2014 ... being a Presenting Sponsor at the Free to Breathe ... Rhode Island. Free to Breathe is a non-profit organization ... from this event will help fund lung cancer research, ... to help navigate their disease and treatment options. , ...
(Date:7/30/2014)... July 30, 2014 Today, Gen. Arthur ... Coalitions of America (CADCA) , the nation’s leading substance ... to the New York Times Editorial Board’s ... July 27th. , “CADCA is disappointed in the ... call for national marijuana legalization. The move is shortsighted ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The global digital ... 2013 and is expected to grow at a CAGR of ... The demand for digital pathology is growing and is expected ... The use of scanners and image analysis software enable pathologists ... for patients. , In 2013, the North American market was ...
(Date:7/30/2014)... (PHILADELPHIA) Up to 20 percent of Parkinson,s ... a common but largely unrecognized challenge: the occurrence ... gambling, sexual behavior, eating, or spending. Yet the ... limit or complicate treatment options. A team of ... the University of Pennsylvania and the Parkinson,s Disease ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Effective ... is now accepting Highmark Blue Cross Blue Shield ... licensed dietetic nutritionist, Nourish Nutrition and Health opened ... downtown Pittsburgh, in Wexford. , The basis ... Health revolve around informing clients on the simplicity ...
Breaking Medicine News(10 mins):Health News:Rhode Island Medical Imaging Announces Partnership with Free to Breathe 2Health News:Rhode Island Medical Imaging Announces Partnership with Free to Breathe 3Health News:CADCA Responds to New York Times Editorial Board's Call for Marijuana Legalization 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 4Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 5Health News:Penn researchers: Naltrexone may diminish impulse control disorders in Parkinson's disease patients 2Health News:Nourish Nutrition and Health Now Accepting Highmark Insurance 2
... Dec. 13 (HealthDay News) -- In the aftermath of a ... the U.S. National Transportation Safety Board is recommending a nationwide ... devices, except in emergencies. According to media reports, the ... fatal pileup that occurred last year in Gray Summit, Mo. ...
... 14, 2011Caffeine is regarded by some as being a potent ... exercise performance. A range of expert opinions capture the scope ... in Journal of Caffeine Research , a quarterly peer-reviewed ... available online at www.liebertpub.com/jcr . Led by ...
... WASHINGTON -- A new Institute of Medicine report specifies ... Administration should require before allowing tobacco companies to sell ... of reducing the health risks of tobacco use. ... of a comprehensive strategy to lower tobacco-related death and ...
... an animal model is a difficult task, but Thomas ... Reporting in the Proceedings of the ... immunologists found that a specialized "human immune system" mouse model ... tick-borne infection known as relapsing fever, caused by the bacteria ...
... of its ongoing efforts to ensure safe, effective and ... joined the ABIM Foundation and eight other medical specialty ... choices by physicians and patients to improve health outcomes, ... dollars. The ACR will develop a list ...
... German . Compared to Neanderthals, modern humans have ... lobes and olfactory bulbs also suggest a combined use of ... of brain size is intimately linked to the evolution of ... independently evolved brains of roughly the same size but with ...
Cached Medicine News:Health News:U.S. Safety Board Urges Nationwide Ban on Drivers' Use of Cellphones 2Health News:New report identifies research needed on 'modified risk' tobacco products 2Health News:New report identifies research needed on 'modified risk' tobacco products 3Health News:Jefferson researchers mirror human response to bacterial infection and resolution in mice 2Health News:ACR in Choosing Wisely campaign to promote wise use of resources among physicians and patients 2Health News:Follow your nose 2
Straight shafts with 1 x 2 teeth. Serrated handle with polished finish. Delicate teeth....
Straight shafts with 0.12 mm teeth and 5 mm tying platform. Serrated handle with polished finish. Manufactured in titanium....
Angled 45 degree shafts with 0.5 teeth and 6 mm tying platform. Polished finish....
Angled 45 degree shafts 8 mm long with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Medicine Products: